In biology, a neoantigen refers to a novel antigen that arises from a mutation in the DNA of a normal cell.

BioRay introduces the initiation of its Phase I clinical trial with the first patient for BRY812, a new LIV-1 focused antibody drug conjugate.

CDK4 inhibitors can inhibit the formation of complexes between CDK4 and cyclin D, block ATP binding, thereby severing upstream growth signals, and prevent the transition from G1 to S phase.

This article summarized the latest R&D progress of Triclabendazole, the Mechanism of Action for Triclabendazole, and the drug target R&D trends for Triclabendazole.

In biology, a mutation is a permanent alteration to the nucleotide sequence of the genome of an organism, virus, or extrachromosomal DNA.

Ventyx Biosciences reports outcomes of the second phase study of VTX958 in moderate-to-severe plaque psoriasis patients and delivers a company update.

This article summarized the latest R&D progress of Prazepam, the Mechanism of Action for Prazepam, and the drug target R&D trends for Prazepam.

The 2023 ESMO Congress marked a pivotal moment with the disclosure of a clinical trial for Osimertinib mesylate in EGFR-mutated NSCLC patients, opening avenues for further increases in its clinical efficacy.

Last year belonged to the realm of Pfizer's COVID-19 small molecule treatments, while this year is dominated by GLP-1 injectable and oral therapies.

The overexpression of the anti-apoptotic factor Myeloid Cell Leukemia 1 (MCL-1), caused by the activation of CDK9, will lead to the transformation of malignant tumor cells. Therefore, inhibiting CDK9 will downregulate MCL-1, thereby suppressing tumor growth.

This article summarized the latest R&D progress of Raloxifene Hydrochloride, the Mechanism of Action for Raloxifene Hydrochloride, and the drug target R&D trends for Raloxifene Hydrochloride.

The recent ESMO Congress presented noteworthy clinical trial results of Givastomig, paving the way for a detailed exploration of its therapeutic potential in solid tumors.